Thermo Fisher Scientific, Inc.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8835561023
USD
575.24
-5.13 (-0.88%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Thermo Fisher Scientific, Inc. stock-summary
stock-summary
Thermo Fisher Scientific, Inc.
Pharmaceuticals & Biotechnology
Thermo Fisher Scientific Inc. develops, manufactures and sells a range of products. The Company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. It offers its products and services through various brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services. Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines. Analytical Instruments segment provides a broad offering of instruments, consumables, software and services that are used for a range of applications in the laboratory. Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Services segment offers products and solutions needed for the laboratory.
Company Coordinates stock-summary
Company Details
168 3rd Ave , WALTHAM MA : 02451-7551
stock-summary
Tel: 1 781 62210001 781 6221111
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 265 Schemes (33.29%)

Foreign Institutions

Held by 730 Foreign Institutions (29.46%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Marc Casper
Chairman of the Board, President, Chief Executive Officer
Mr. Thomas Lynch
Lead Independent Director
Ms. R. Alexandra Keith
Director
Mr. Nelson Chai
Independent Director
Dr. C. Martin Harris
Independent Director
Dr. Tyler Jacks
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
10,855 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,619 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 205,941 Million (Large Cap)

stock-summary
P/E

26.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.31%

stock-summary
Debt Equity

0.57

stock-summary
Return on Equity

13.56%

stock-summary
Price to Book

4.08